home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,217 rows where filing_year = 2020 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

filing_period 4

  • second_quarter 317
  • fourth_quarter 309
  • first_quarter 296
  • third_quarter 295

issue_code 1

  • PHA · 1,217 ✖

filing_year 1

  • 2020 · 1,217 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2420550 AMERICAN COLLEGE OF CLINICAL PHARMACY 7ec9c022-a5a5-48ea-8f5b-be35876d8cd7 Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2020 first_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2020-04-01T12:27:56.353000-04:00
2420586 4C COMMUNICATIONS, INC. 58c7edb3-ff7e-43d2-bf66-477a55476564 Q1 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2020 first_quarter PHA Discussion on pharmaceutical drug pricing; cost of pharmaceutical drugs in the Medicare Part D program HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-04-01T14:45:17.390000-04:00
2421630 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION bb244e5d-47db-45c0-a5ac-4d67906469a2 Q1 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2020 first_quarter PHA Discussed potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2020-04-07T11:12:22.827000-04:00
2421744 HOLLAND & KNIGHT LLP 8c2c4492-5eb4-481f-b44b-302955b119f4 Q1 HOLLAND & KNIGHT LLP 18466 TEVA PHARMACEUTICALS USA, INC. 2020 first_quarter PHA Drug pricing; Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748). HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-04-07T14:05:58.950000-04:00
2421824 JOHNSON MATTHEY INC. df03fd0f-2edd-4fb2-b4fc-9941d9bfbe51 Q1 JOHNSON MATTHEY INC. 401104441 JOHNSON MATTHEY INC. 2020 first_quarter PHA H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers. HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2020-04-07T14:47:47.110000-04:00
2421873 PENN AVENUE PARTNERS eb123b0f-309f-4b74-9b1d-8f6e932902d4 Q1 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2020 first_quarter PHA Regulatory and legislative issues impacting Alkermes. S.3312: Crisis Stabilization and Community Reentry Act of 2020. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-07T16:09:25.093000-04:00
2421978 RED+BLUE STRATEGIES a7d506d3-b50b-443f-90e1-33cdbbe879aa Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2020 first_quarter PHA H.R. 748 - CARES Act - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond. H.R. 6201 - Families First Coronavirus Response Act - Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Issues related to supporting programs and institutions supporting during the current pandemic. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-08T10:20:04.430000-04:00
2421988 RED+BLUE STRATEGIES 382b6856-f8f1-4730-9076-77094dfb061b Q1 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2020 first_quarter PHA H.R. 748 - CARES Act - Issues related to supporting the national work fighting COVID-19 and ensuring that antibiotics are available during the COVID-19 crisis and beyond and OTC monograph reform is address to enhance patient safety. H.R. 6201 - Families First Coronavirus Response Act - Issues related to ensuring that the federal government is best supporting the public good with a focus on ensuring there is a strong antibiotics pipeline to fight secondary infections and over the counter medications are safe and secure. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Issues related to supporting programs and institutions supporting during the current pandemic. S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. H.R. 3443 - The OTC Monograph Safety Innovation and Reform Act of 2019 - Support for policies that enable OTC monograph reform. Issues related to creating a listing mechanism for dietary supplements. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-08T10:40:15.957000-04:00
2422418 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 89923d8a-7e0c-448b-8c3d-f51885cdb790 Q1 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2020 first_quarter PHA HR 4392- To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. H.R. 3. Lower Prescription Drug Costs Now Act - legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE   252275 0 0 2020-04-09T12:13:57.773000-04:00
2422478 THORSEN FRENCH ADVOCACY LLC d3907e17-4ce0-4503-aaf5-847e59ca0439 Q1 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2020 first_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. Issues related to regulation of prescription opioid medication. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-09T14:31:17.347000-04:00
2422507 THORSEN FRENCH ADVOCACY LLC 066de8e3-4488-4bed-b338-0abddb6a0b73 Q1 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2020 first_quarter PHA Issues related to pharmaceutical market value. H.R.965/S.340: CREATES Act of 2019. Proposed Notice of Benefit and Payment Parameters (NBPP) Rule for 2021. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-04-09T14:43:38.940000-04:00
2422628 HOLLAND & KNIGHT LLP f3a255db-9b64-4cae-84fa-001ef767403b Q1 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2020 first_quarter PHA Drug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, the consumer price index, generic drugs. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-04-09T16:33:26.343000-04:00
2422810 ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) daa50085-ced8-4173-b234-80315e6b906a Q1 ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 400637926 ACCREDITATION COMMISSION FOR HEALTH CARE 2020 first_quarter PHA Issues related to compounding pharmacy practice. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2020-04-10T11:15:02.713000-04:00
2422812 ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 34dfa5a4-8329-42c2-9501-e8c6011a13d9 Q1 ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 400637926 PANTHERX 2020 first_quarter PHA Issues related to the specialty pharmacy practice.       0 0 2020-04-10T11:16:04.127000-04:00
2422859 TAUZIN STRATEGIC NETWORKS 3104fc41-0609-4fc0-9591-7683a810be39 Q1 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2020 first_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-10T11:38:02.470000-04:00
2423209 ACG ADVOCACY ea4f3dc9-683e-4b20-8ea9-af4cdb082292 Q1 ACG ADVOCACY 2057 WALGREEN CO. 2020 first_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. Public Health Crisis. H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2020-04-10T17:26:56.807000-04:00
2423416 REPUBLIC CONSULTING, LLC 6255e1be-ca8b-4b8d-9333-051088e2d213 Q1 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2020 first_quarter PHA Monitor Data and Science Policy. Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-11T14:13:24.893000-04:00
2423528 RED+BLUE STRATEGIES ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8 Q1 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2020 first_quarter PHA H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-12T14:44:52.997000-04:00
2423559 ACG ADVOCACY 8ac2a863-9d50-4489-b956-70359eccc345 Q1 ACG ADVOCACY 2057 GENENTECH INC 2020 first_quarter PHA Drug Pricing Issues. Public Health Crisis. H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office 40000   0 0 2020-04-13T08:44:23.677000-04:00
2423609 THE KUTLER GROUP bbd4c069-8ec6-4865-994d-3398447667e1 Q1 THE KUTLER GROUP 401103966 PRIME THERAPEUTICS 2020 first_quarter PHA drug pricing issues monitor Covid 19 legislation HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2020-04-13T10:11:03.830000-04:00
2423829 SOUTHERN ILLINOIS UNIVERSITY 2cccd489-e899-4c6c-8bc8-b8e966566bbf Q1 SOUTHERN ILLINOIS UNIVERSITY 6564 SOUTHERN ILLINOIS UNIVERSITY 2020 first_quarter PHA Met with Congressman LaHood on Feb 20 at the Simmons Cancer Institute to talk about 340B pricing and other cancer-related issues including Simmons outreach to the African American community to discuss cancer testing and prevention. HOUSE OF REPRESENTATIVES   11250 0 0 2020-04-13T11:56:23.847000-04:00
2424116 MARSHALL & POPP, LLC f076db48-cca4-4510-9322-7c747f9c0d32 Q1 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2020 first_quarter PHA Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index. Issues related to the COVID-19 pandemic. H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. H.R.6201: Families First Coronavirus Response Act. H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office 60000   0 0 2020-04-13T14:54:20.970000-04:00
2424157 MARSHALL & POPP, LLC 98634ee8-1d1d-482c-8299-61abcb39dc61 Q1 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2020 first_quarter PHA Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3/: Lower Drug Costs Now Act of 2019, and H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index. Issues related to the COVID-19 pandemic. H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. H.R.6201: Families First Coronavirus Response Act. H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office 50000   0 0 2020-04-13T15:13:31.190000-04:00
2424161 MARSHALL & POPP, LLC ed1f9520-700a-4328-ac42-dba0018eabb1 Q1 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2020 first_quarter PHA Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019; and H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index. Issues related to the COVID-19 pandemic. H.R.6074: Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. H.R.6201: Families First Coronavirus Response Act. H.R.748: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),SENATE,White House Office 60000   0 0 2020-04-13T15:17:32.377000-04:00
2424185 WAXMAN STRATEGIES 5e45c6d5-df55-4871-afcd-fbbaafe8329e Q1 WAXMAN STRATEGIES 401103693 340B HEALTH 2020 first_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-13T15:26:38.543000-04:00
2424189 FARRAGUT PARTNERS LLP 5d4184c5-24a6-4b76-a5ee-9de9b46a1953 Q1 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2020 first_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-04-13T15:28:39.783000-04:00
2424483 CONNECT 4 STRATEGIES, LLC d7392111-2c6e-4984-a4f5-c9bd1ee9c2ef Q1 CONNECT 4 STRATEGIES, LLC 401103720 FCS FOUNDATION 2020 first_quarter PHA FDA processes HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-13T20:12:07.250000-04:00
2424616 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) b9fc3fa3-dcd3-42aa-aa64-04a0344b7a1d Q1 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2020 first_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to continuation of prescription drug access and testing during COVID crisis. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2020-04-14T08:57:36.837000-04:00
2424950 ISEMAN & ASSOCIATES LLC 43a8d74e-2b36-48d1-82cf-f52d9a5fe37c Q1 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2020 first_quarter PHA Monitoring biotech legislation; prescription drug prices HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2020-04-14T12:30:12.947000-04:00
2424977 LUNGREN LOPINA LLC 0363409a-77f0-44b3-9ede-8d7c117da13d Q1 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2020 first_quarter PHA Fair treatment for US based pharmaceutical ingredients Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-04-14T12:58:22.030000-04:00
2424997 GOVERNMENT COUNSEL, LLC 1bf177eb-2d39-491b-a6cc-c65f7b025ae1 Q1 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2020 first_quarter PHA Issues related to ARCOS data and suspicious order record requirements and reporting (S.3070-Preventing Pill Mills Through Data Sharing Act, S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019); importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-14T13:21:29.807000-04:00
2425081 TARPLIN, DOWNS & YOUNG, LLC 106afdfb-a7a5-47a5-869c-b1637e19a17a Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 ASTRAZENECA 2020 first_quarter PHA Drug coverage & reimbursement no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 1895 - Lower Health Care Costs Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-14T14:12:52.797000-04:00
2425145 POLSINELLI PC eca5250c-a816-4e72-a9b2-d878e6cf13bc Q1 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2020 first_quarter PHA S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act H.R. 6201, Families First Coronavirus Response Act H.R. 748, CARES Act Review of Administration drug pricing policies HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-04-14T14:49:19.267000-04:00
2425322 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION fd3dcc33-0efd-4a0a-93f1-e53de890c714 Q1 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2020 first_quarter PHA In-office Compounding Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2020-04-14T16:15:14.947000-04:00
2425419 INDEPENDENT PHARMACY COOPERATIVE eb9afb29-08e4-4456-ba77-8d5e855f1908 Q1 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2020 first_quarter PHA The Prescription Drug Pricing Reduction Act S. 2543-IPC supports. Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale. Support regulations that would eliminate pharmacy DIR. IPC supports Pharmacists as providers under Medicare Part D IPC supports Pharmacists as Imunnizers First Families Coronavirus Response Act 2020. IPC supports The Coronavirus Aid, Relief and Economic Security Act 2020. IPC supports Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   30000 0 0 2020-04-14T17:02:49.760000-04:00
2425448 MCDERMOTT+ LLC 8021ebd5-c0fc-4e12-a41c-6f5afb7ddbe7 Q1 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2020 first_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-14T17:24:00.940000-04:00
2425534 RUBICON ADVISORS, LLC bb8b4a93-a8ea-47e2-be1f-940c78050da4 Q1 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2020 first_quarter PHA Prescription Drug User Fee HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2020-04-15T08:26:37.967000-04:00
2425536 RUBICON ADVISORS, LLC 0c67f07c-4d19-41bb-b777-9ca0abbea2b3 Q1 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2020 first_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2020-04-15T08:32:38.987000-04:00
2425537 RUBICON ADVISORS, LLC 441f1a37-d251-4646-b14c-3f54730e647c Q1 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2020 first_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2020-04-15T08:38:39.793000-04:00
2425657 NATIONAL RURAL HEALTH ASSOCATION aa0f7ced-218a-4978-9f64-78d11b1ba7f2 Q1 NATIONAL RURAL HEALTH ASSOCATION 53048 NATIONAL RURAL HEALTH ASSOCATION 2020 first_quarter PHA The 340B Program and drug pricing Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE   291971 0 0 2020-04-15T09:50:20.760000-04:00
2425851 RUBICON ADVISORS, LLC 5b4ee2bd-aece-4572-a935-83ac92fb71c2 Q1 RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2020 first_quarter PHA Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 20000   0 0 2020-04-15T11:06:18.580000-04:00
2425928 TARPLIN, DOWNS & YOUNG, LLC 7817b081-cb35-4d1d-a406-1dbfe9adeb32 Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 BIOTECHNOLOGY INDUSTRY ORGANIZATION 2020 first_quarter PHA H.R. 1781 - Payment Commission Data Act of 2019 H.R. 938 - the BLOCKING Act of 2019 H.R. 1520 - the Purple Book Continuity Act of 2019 H.R. 1503 - the Orange Book Transparency Act of 2019 H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 H.R. 965 - the CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions For Patients Act of 2019 H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 80000   0 0 2020-04-15T11:34:48.310000-04:00
2426032 CARD & ASSOCIATES, LLC ea970a29-aeb1-4f9c-ae6f-ce71c0146235 Q1 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2020 first_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing S 1895 Lower Healthcare Costs Act HR 2296 Fair Accountability and Innovative Research Drug Pricing Act HR 2376 Prescription Pricing for the People Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-15T12:10:25.597000-04:00
2426123 MEHLMAN CONSULTING, INC. 83aa9440-05dd-4527-b8f2-4a0db34318e9 Q1 MEHLMAN CONSULTING, INC. 284950 AARP, INC. 2020 first_quarter PHA S.1895 - Lower Health Care Costs Act including issues relating to drug pricing Older Americans Reauthorization Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019. House prescription drug price transparency legislation. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-15T12:24:52.653000-04:00
2426309 AMERICAN VETERINARY MEDICAL ASSOCIATION d3e22154-dd43-4eda-bfdc-5af0c29c41c5 Q1 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2020 first_quarter PHA GFI 256 FDA Compounding Guidance; Agriculture, Dept of (USDA),Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE 320000   0 0 2020-04-15T13:29:48.717000-04:00
2426333 TARPLIN, DOWNS & YOUNG, LLC 4fed2622-8609-4194-98ba-ec63a3f7b19d Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2020 first_quarter PHA Importation of prescription drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844) Opioid Abuse - General issues related to opioid drug abuse (Implementation of Public Law 115-271) Implementation of Public Law 113-54 (DSCSA) Issues Related to ARCOS data and suspicious order record requirements & reporting Block, Report, and Suspend Suspicious Shipments Act of 2019 (H.R. 3878) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-04-15T13:34:55.107000-04:00
2426926 POLITICAL CAPITAL, LLC 91d55450-3818-4e66-accd-5fbb06de315a Q1 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2020 first_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2020-04-15T16:18:41.893000-04:00
2426933 POLITICAL CAPITAL, LLC 1f0cf912-97fa-439a-b132-5e2df1926af5 1T POLITICAL CAPITAL, LLC 401104260 PINE PHARMACEUTICALS 2020 first_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 1 2020-04-15T16:22:43.757000-04:00
2426954 POLITICAL CAPITAL, LLC 080dfbbd-e9c3-4a39-93bf-6be68da8ade0 Q1 POLITICAL CAPITAL, LLC 401104260 STOKES PHARMACY 2020 first_quarter PHA Compounding Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2020-04-15T16:26:48.770000-04:00
2427075 BROYDRICK & ASSOCIATES 7ffacda4-c283-4b91-ab36-b86c1112a0cd Q1 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2020 first_quarter PHA Drug shortages and FDA approval. USTR acceptance. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-04-15T17:25:25.787000-04:00
2427124 BROYDRICK & ASSOCIATES a7dfd8b6-1456-46b4-afee-1b34a87be33b Q1 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2020 first_quarter PHA Funding new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-04-15T17:44:42.340000-04:00
2427194 MEHLMAN CONSULTING, INC. d2803cfd-d9c6-4f3d-aea6-a595c4703675 Q1 MEHLMAN CONSULTING, INC. 284950 AMERICA'S HEALTH INSURANCE PLANS 2020 first_quarter PHA Prescription drug pricing Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2020-04-15T21:10:06.653000-04:00
2427204 MEHLMAN CONSULTING, INC. d7ad3d1e-3a04-45b4-b626-f027a25c2bba Q1 MEHLMAN CONSULTING, INC. 284950 ASCENSION HEALTH ALLIANCE 2020 first_quarter PHA 340B Drug Pricing Program. S.1895 - Lower Health Care Costs Act H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127 H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136 Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19 Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-15T21:37:08.847000-04:00
2427208 MEHLMAN CONSULTING, INC. 005221bd-0642-4a66-b0f5-42ff6b48d430 Q1 MEHLMAN CONSULTING, INC. 284950 ASSOCIATION OF ACCESSIBLE MEDICINES 2020 first_quarter PHA Medicaid and Medicare drug pricing. Prescription drug pricing. H.R. 965 - CREATES Act of 2019. H.R. 985 - FAST Generics Act of 2019. S.1895 - Lower Health Care Costs Act. S. 440 - PACED Act H.R. 938 - BLOCKING Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-15T21:40:09.347000-04:00
2427221 MEHLMAN CONSULTING, INC. fb2ed54a-7c8d-470b-a570-2768031afe58 Q1 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2020 first_quarter PHA Prescription drug pricing. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-15T21:58:12.890000-04:00
2427360 NATIONAL ASSOCIATION OF CHAIN DRUG STORES a75529e2-7f7e-4e30-858d-f3096ba335aa Q1 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2020 first_quarter PHA H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019 H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act HOUSE OF REPRESENTATIVES,SENATE   460000 0 0 2020-04-16T08:52:53.837000-04:00
2427362 MR. VINCENT A. PANVINI 03710cad-aa75-4e6f-902f-2a60447a9b7b Q1 MR. VINCENT A. PANVINI 401008845 PHRMA 2020 first_quarter PHA Position on Price Controls; Intellectual Property Rights; Illegal Importation of Biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-04-16T08:56:55.847000-04:00
2427367 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) de0a74a0-d136-4aea-9f57-4e32ac274798 Q1 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 AMAZON.COM 2020 first_quarter PHA Drug pricing & transparency Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT) 60000   0 0 2020-04-16T08:56:57.080000-04:00
2427421 MCDERMOTT+ LLC 0ad11802-0b52-4cdf-b702-b2ed24f79302 Q1 MCDERMOTT+ LLC 401103287 CAMPAIGN FOR SUSTAINABLE DRUG PRICING 2020 first_quarter PHA S. 1895 - Lower Health Care Costs Act H.R. 985 - FAST Generics Act of 2019 S. 2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-04-16T09:25:07.767000-04:00
2427456 THE MATHIS HARPLE GROUP e392d317-a9ad-42e6-bc06-949740706704 Q1 THE MATHIS HARPLE GROUP 322911 PILMA 2020 first_quarter PHA HR 3, Price Controls, Intellectual Property Rights, Patent Protections HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2020-04-16T09:38:16.307000-04:00
2427483 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 80ddeddc-2961-4dc5-9c86-75490e4efdbf 1T CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2020 first_quarter PHA Issues related to the 340B drug discount program and drug pricing policies Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2020-04-16T09:46:24.477000-04:00
2427501 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 7e0fd076-e271-4082-b3e5-da2626da6471 1T CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2020 first_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 1 2020-04-16T09:50:28.300000-04:00
2427528 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 827811d9-41a5-4d80-b3cc-c4bd38949810 1T CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2020 first_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 1 2020-04-16T09:56:37.020000-04:00
2427969 THE MATHIS HARPLE GROUP df9326a4-fd23-4469-a766-2b44f661db67 Q1 THE MATHIS HARPLE GROUP 322911 PHRMA 2020 first_quarter PHA Price Controls, Intellectual Property Rights, Patent Protections, HR3 HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-04-16T11:43:41.293000-04:00
2428013 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 4cf73ccf-fcab-4f34-810c-ded7c53ad4aa Q1 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 30212 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2020 first_quarter PHA Drug pricing, Direct and Indirect remuneration fees, Medicare, COVID-19 Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2020-04-16T11:52:59.257000-04:00
2428500 MEHLMAN CONSULTING, INC. 3748ab5e-997d-4176-93f8-3f6dda809949 Q1 MEHLMAN CONSULTING, INC. 284950 FOOD ALLERGY RESEARCH & EDUCATION (FARE) 2020 first_quarter PHA Labeling of allergens. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-04-16T13:13:50.327000-04:00
2428775 BLUECROSS BLUESHIELD OF TENNESSEE 32e45db2-da71-4a4f-92bf-596136eb1434 Q1 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2020 first_quarter PHA Opioid and prescription drug pricing issues; Rx drug rebates; regulation of pharmacy benefit managers; CREATES Act;. H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 HOUSE OF REPRESENTATIVES,SENATE   15000 0 0 2020-04-16T14:07:22.337000-04:00
2428989 BROWN & FORTUNATO, P.C. 55e71d74-a2a7-456c-881c-ab91a634af22 Q1 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2020 first_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program. Issues related to H.R. 4945 - Safeguarding Medicare Access to Respiratory Therapy Act of 2019; H.R. 1865 - Further Consolidated Appropriations Act, 2020; H.R. 748 - CARES Act; H.R. 6201 - Family First Coronavirus Response Act. Issues related to H.R. 6218 and S. 3457 - The Preserving Medicare Access to Home Infusion Act. Centers For Medicare and Medicaid Services (CMS) 20000   0 0 2020-04-16T14:57:24.613000-04:00
2429137 MASSACHUSETTS MEDICAL SOCIETY 398c6237-536b-45d0-83ca-b14fff0aaefe Q1 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2020 first_quarter PHA Prescription Drugs H.R. 3 - The Lower Drug Costs Now Act Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   90000 0 0 2020-04-16T15:38:08.410000-04:00
2429313 KOUNTOUPES DENHAM CARR & REID, LLC 0dad3a65-2c9c-4a1d-a62b-20b53fc1ccf8 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2020 first_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. Issues related to H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including drug supply chain dynamics. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-16T16:34:00.480000-04:00
2429863 VAN SCOYOC ASSOCIATES 3604a3bd-c709-42b4-9c4b-eccf080aff2d Q1 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2020 first_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation Temperature monitoring technology for vaccines HOUSE OF REPRESENTATIVES 30000   0 0 2020-04-17T05:28:38.750000-04:00
2430057 AARP 43d50a51-cb21-459a-9c03-21525d726a33 Q1 AARP 1694 AARP 2020 first_quarter PHA H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act. H.R. 6201, Families First Coronavirus Response Act; H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act - Discussed Medicare enrollment national open enrollment period, medical expense deduction, cost-sharing protections for commercial/private health insurance holders, telehealth access, nursing homes, virtual visitation, home and community-based services, Older Americans Act programs, Medicare home health care, and family caregiving, no-cost COVID-19 testing, equitable relief payments, retirement savings tax relief, suspensions of foreclosures and evictions, expanded unemployment benefits, paid sick and family leave, affordable broadband, and government operations, among other issues. H.R. 3, Elijah E. Cummings Lower Cost Drugs Now Act. S. 2543, the Prescription Drug Pricing Reduction Act. S.64/H.R. 2375 - the Preserve Access to Generics and Biosimilars Act. H.R. 1499 - the Preserving Consumer Access to Generics Act. H.R. 2113 - the Prescription STAR Act. H.R. 2296/S.1391 - The FAIR Drug Pricing Act. S.1416 - the Affordable Prescriptions for Patients Act. S.1437, the Drug-price Transparency in Communications (DTC) Act. S.551, the REFUND Act. S.1209, the REMEDY Act. S. 474/H.R. 2069, the SPIKE Act. H.R. 19/S. 3129, Lower Cost More Cures Act. Administration for Children & Families (ACF),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Federal Deposit Insurance Corporation (FDIC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Indian Health Service,Internal Revenue Service (IRS),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of the Comptroller of the Currency (OCC),Pension Benefit Guaranty Corporation (PBGC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office   2210000 0 0 2020-04-17T07:49:26.393000-04:00
2430212 RUBICON ADVISORS, LLC 42c0770f-f682-46e4-ac49-5c31309fb8d5 1A RUBICON ADVISORS, LLC 315091 AVET PHARMACEUTICALS 2020 first_quarter PHA GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM AND COVID-19 FDA DRUG SHORTAGES HOUSE OF REPRESENTATIVES 30000   0 0 2020-04-17T09:00:40.367000-04:00
2430260 ELI LILLY AND COMPANY 056ef3b1-9219-4e18-89ae-18f3c627f9d3 Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2020 first_quarter PHA Hospital discounts; 340B program Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1290000 0 0 2020-04-17T09:31:10.340000-04:00
2430370 LINCOLN PARK GROUP L.L.C. 59a283e4-f8f1-44a3-a799-02c2caa78fe9 Q1 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2020 first_quarter PHA Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-04-17T10:02:32.733000-04:00
2430448 WINNING STRATEGIES WASHINGTON 0ee28ee8-c53c-452d-ac4c-0da415b736c9 Q1 WINNING STRATEGIES WASHINGTON 50796 KALEO 2020 first_quarter PHA Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-04-17T10:16:53.520000-04:00
2430480 UNIVERSITY OF IOWA 92344024-7f13-47b5-95cb-dbfb0850ab00 Q1 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2020 first_quarter PHA N/A Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE   70000 0 0 2020-04-17T10:23:06.180000-04:00
2430631 FLYNN & ASSOCIATES, INC. 93a86536-68be-4b39-98d8-17b50cafbd14 Q1 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2020 first_quarter PHA H.R. 3 Lower Drug Prices- Cummings Act Drug importation from Canada HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-17T10:40:30.880000-04:00
2430661 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION fc01841f-aa2d-4cde-9384-d67629fbf0e8 Q1 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2020 first_quarter PHA H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019; H.R. 5198, the Patients' Right to Know Their Medication Act of 2019; H.R. 5304, the PBM Transparency in Prescription Drug Costs Act Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   440000 0 0 2020-04-17T10:44:36.663000-04:00
2431266 KOUNTOUPES DENHAM CARR & REID, LLC 55406673-87ff-46c3-8ee3-fcda40235c3b Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2020 first_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3,The Lower Drug Costs Now Act. H. R. 1865. Issues related to H. R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including supply chain issues for generic medicines. Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),White House Office 60000   0 0 2020-04-17T11:56:52.660000-04:00
2431377 KOUNTOUPES DENHAM CARR & REID, LLC 763954e0-17b9-456a-accb-b5ff89078a22 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2020 first_quarter PHA Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to H.R.748, Coronavirus Aid,Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-17T12:12:18.907000-04:00
2431390 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 88f2e40b-fbc4-4677-b20c-b21bd92b780a Q1 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2020 first_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting (S. 3070, S. 2686, HR 4814) Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Preventing Pill Mills Through Data Sharing Act - S. 3070 Suspicious Order Identification Act of 2019 - S. 2686 Suspicious Order Identification Act of 2019 - HR 4814 Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   313210 0 0 2020-04-17T12:13:22.103000-04:00
2431437 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 5d0404cf-b507-4bdd-9886-f83aa6d2fc87 Q1 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 323876 BLUE CROSS AND BLUE SHIELD OF KANSAS INC 2020 first_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Rx Rebates; Biosimilars; Drug approval; Drug patents, generic drugs, Part D Reform; Civica Rx H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby [D-IL-1](Introduced 03/08/2019) H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David [D-RI-1](Introduced 02/05/2019) H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6](Introduced 09/19/2019) H.R.275 - 116th Congress (2019-2020) Medicare Prescription Drug Price Negotiation Action of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large](Introduced 01/08/2019) H.R.448 - 116th Congress (2019-2020) Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7](Introduced 01/10/2019) H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35](Introduced 02/07/2019) S.3092 - 116th Congress (2019-2020) Expanding Access to Low-Cost Generics Act of 2019 Sponsor: Sen. Smith, Tina [D-MN](Introduced 12/18/2019) H.R.19 - 116th Congress (2019-2020) Lower Costs, More Cures Act of 2019 Sponsor: Rep. Walden, Gred [R-OR-2](Introduced 12/09/2019) H.R.6193 - 116th Congress (2019-2020) Medication Access in Emergencies Act of 2020 Sponsor: Rep Pappas, Chris [D-NH-1](Introduced 03/11/2020) H.R.5578 - 116th Congress (2019-2020) Recall Unsafe Drugs Act of 2020 Sponsor: Rep. Delauro, Rosa [D-CT-3](Introduced 01/10/2020) H.R.5691 - 116th Congress (2019-2020) Insulin Affordability Data Collection Act Sponsor: Rep. Craig, Angie [D-MN-2](Introduced 01/28/2020) H.R.5894 - 116th Congress (2019-2020) Transparency in Prescription Drug Advertising Act Sponsor: Rep Davids, Sharice [D-KS-3](Introduced 02/13/2020) HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-04-17T12:18:35.750000-04:00
2431560 KAISER FOUNDATION HEALTH PLAN INC. 322c13ec-542e-4554-b20d-66c9b0d30f31 Q1 KAISER FOUNDATION HEALTH PLAN INC. 21027 KAISER FOUNDATION HEALTH PLAN INC 2020 first_quarter PHA S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act S. 3052, Grassley, the US, Mexico and Canada Trade Agreement Implementation Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D HR 4378, Continuing Appropriations and Health Extenders Act S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   670000 0 0 2020-04-17T12:33:12.550000-04:00
2431640 NELSON MULLINS RILEY & SCARBOROUGH 4f08bc88-aa7b-49f3-9ac2-4f356075c86e Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2020 first_quarter PHA Issues related to the 340B Drug Pricing Program, biomedical research and Medicare, COVID-19/Coronavirus Response Legislative Initiatives HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-04-17T12:41:30.817000-04:00
2431789 MASSACHUSETTS BIOTECHNOLOGY COUNCIL 4f1da57a-bb66-4faa-9828-597be39adf0a Q1 MASSACHUSETTS BIOTECHNOLOGY COUNCIL 400271247 MASSACHUSETTS BIOTECHNOLOGY COUNCIL 2020 first_quarter PHA Issues associated with proposed changes to the 340B Discount Drug Program Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Patent & Trademark Office (PTO),SENATE   25000 0 0 2020-04-17T13:12:15.377000-04:00
2431907 BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 0af66202-d6b7-44f3-8222-f6533ead8c19 Q1 BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 401104621 BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 2020 first_quarter PHA HR 4712, S3271 Fairness in Orphan Drug Exclusivity Act: General lobbying pertaining to opioid crisis; controlled substances and specialty pharmacies HOUSE OF REPRESENTATIVES,SENATE   100000 0 0 2020-04-17T13:26:33.017000-04:00
2431940 E3 STRATEGIC CONSULTING GROUP 5213a711-2fb8-4a5c-b217-c4292e5368af Q1 E3 STRATEGIC CONSULTING GROUP 401104104 HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) 2020 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-04-17T13:29:41.237000-04:00
2431948 E3 STRATEGIC CONSULTING GROUP a6d85cca-19cc-43a9-9212-ca335d1d53ad Q1 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2020 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-04-17T13:30:42.320000-04:00
2431954 PARK STREET STRATEGIES, LLC 9a287153-3999-4436-8556-6560687e0b2f Q1 PARK STREET STRATEGIES, LLC 401103554 MASSACHUSETTS BIOTECHNOLOGY COUNCIL 2020 first_quarter PHA Monitor legislation to change 340B Discount Drug Program Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Patent & Trademark Office (PTO),SENATE 5000   0 0 2020-04-17T13:31:43.290000-04:00
2431988 HCM STRATEGISTS 081a86a7-e803-45d7-af4d-3932ee4c7bb8 Q1 HCM STRATEGISTS 400459263 ALLIANCE OF COMMUNITY HEALTH PLANS 2020 first_quarter PHA 2593, The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 HR 3, The Elijah E. Cummings Lower Drug Costs Now Act       0 0 2020-04-17T13:38:53.297000-04:00
2432257 AMERICAN PHARMACISTS ASSOCIATION 6f30ba35-c63b-46c8-bb80-5096466c1335 Q1 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2020 first_quarter PHA H.R. 789 - To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. H.R. 803 - This bill prohibits Medicare prescription drug plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A "clean claim" is a Medicare claim that is free of defects such as incomplete documentation.) H.R. 1034 - Phair Pricing Act of 2019; To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program S. 640 - To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program, and for other purposes. S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers. S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers. H.R. 3 Lower Drug Costs Now Act of 2019-To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes. S.2543 Prescription Drug Pricing Reduction Act of 2019 -To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes. HR 5304 PBM Transparency in Prescription Drug Cost Act - To amend t… HOUSE OF REPRESENTATIVES,SENATE   34000 0 0 2020-04-17T14:15:11.293000-04:00
2432272 KOUNTOUPES DENHAM CARR & REID, LLC 23d550f4-ab48-4062-a87a-927d069b1791 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2020 first_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 3443/S2740, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-17T14:16:14.783000-04:00
2432367 TWENTY-FIRST CENTURY GROUP, INC. cb74e90e-8742-46d7-9993-4d532bd37a51 Q1 TWENTY-FIRST CENTURY GROUP, INC. 38687 CARDINAL HEALTH, INC. 2020 first_quarter PHA Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response;and the healthcare supply chain. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-04-17T14:32:36.437000-04:00
2432385 ML STRATEGIES, LLC 0bfc5c42-e7dd-4c5c-8732-e16c144b3cd9 Q1 ML STRATEGIES, LLC 25603 LEADING BIOSCIENCES 2020 first_quarter PHA Issues related to potential funding opportunities for Coronavirus (COVID-19)   10000   0 0 2020-04-17T14:34:40.123000-04:00
2432393 KOUNTOUPES DENHAM CARR & REID, LLC 59de80b6-139e-440e-a725-097d1fb869f7 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2020 first_quarter PHA General education about the pharmacy benefit manager/pharmacy industry, including spread pricing proposals and S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program. S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019. Issues related to H.R.748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including provisions relating to the drug supply chain. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-17T14:36:41.257000-04:00
2432396 340B HEALTH 675b4014-4455-49fb-af89-dfea66b51b82 Q1 340B HEALTH 316434 340B HEALTH 2020 first_quarter PHA The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 3, Lower Drug Costs Now Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 5281, Drug Price Transparency in Medicaid Act of 2019; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act; HR 19, Lower Costs, More Cures Act of 2019 Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   363453 0 0 2020-04-17T14:36:42.497000-04:00
2432417 PANNONE LOPES DEVEREAUX & O'GARA LLC 8aab637f-976d-44ec-a2dd-4cbf01b31f42 Q1 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2020 first_quarter PHA Prescription drug pricing. HOUSE OF REPRESENTATIVES     0 0 2020-04-17T14:38:47.277000-04:00
2432609 ACADEMY OF MANAGED CARE PHARMACY 66e763b4-b81e-464b-9146-8f6ea12abbcd Q1 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2020 first_quarter PHA Communication and correspondence on lowering health care costs, support to changes in 42 C.F.R., dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr) and issues related to coronavirus relief. HOUSE OF REPRESENTATIVES,SENATE   51875 0 0 2020-04-17T15:01:39.170000-04:00
2432624 HANCE SCARBOROUGH 5f8b09c3-f560-4a6c-9e98-d2b0a65987db Q1 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2020 first_quarter PHA Issues related to the regulation of pharmacy compounding. HR 1959 Preserving Patient Access to Compounded Medications Act. CARES Act H.R. 748 HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-17T15:02:16.570000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1660.429ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API